Compare Stocks

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PDP Invesco Dorsey Wright Momentum ETF	$94.27 +0.5%	$95.49	$72.68 ▼ $99.60	$1.22B	1.02	26,015 shs	5,283 shs
PMN ProMIS Neurosciences	$1.96 +0.5%	$2.04	$0.95 ▼ $8.95	$37.16M	0.67	37,762 shs	689 shs
RENE Cartesian Growth Co. II	$11.21	$11.11	$10.52 ▼ $11.92	$242.36M	-0.01	62,761 shs	14,898 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PDP Invesco Dorsey Wright Momentum ETF	+0.06%	+1.91%	-4.59%	+7.89%	+27.55%
PMN ProMIS Neurosciences	0.00%	-1.02%	+0.52%	-3.05%	-71.28%
RENE Cartesian Growth Co. II	+0.09%	+0.22%	+0.90%	+1.72%	+6.56%

The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PDP Invesco Dorsey Wright Momentum ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	2.3094 of 5 stars	3.5	4.0	0.0	0.0	1.1	1.7	0.6
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PDP Invesco Dorsey Wright Momentum ETF	0.00	N/A	$97.21	3.12% Upside
PMN ProMIS Neurosciences	3.00	Buy	$8.00	308.16% Upside
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PDP Invesco Dorsey Wright Momentum ETF	N/A	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	$10K	3,716.16	N/A	N/A	$0.20 per share	9.80
RENE Cartesian Growth Co. II	N/A	N/A	$0.40 per share	28.14	($0.64) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PDP Invesco Dorsey Wright Momentum ETF	N/A	N/A	25.46	∞	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	-$13.21M	-$1.13	N/A	N/A	N/A	N/A	N/A	-141.23%	5/20/2024 (Estimated)
RENE Cartesian Growth Co. II	$11.44M	N/A	0.00	∞	N/A	N/A	-65.59%	5.02%	N/A

Latest PDP, RENE, and PMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	PMN ProMIS Neurosciences	N/A	-$0.09	-$0.09	-$0.09	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PDP Invesco Dorsey Wright Momentum ETF	$0.25	0.27%	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A

Latest PDP, RENE, and PMN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/15/2024	PDP Invesco Dorsey Wright Momentum ETF	Quarterly	$0.0275		3/18/2024	3/19/2024	3/22/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PDP Invesco Dorsey Wright Momentum ETF	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	1.46	1.46
RENE Cartesian Growth Co. II	N/A	0.22	0.22

Ownership

Institutional Ownership

Company	Institutional Ownership
PDP Invesco Dorsey Wright Momentum ETF	N/A
PMN ProMIS Neurosciences	50.13%
RENE Cartesian Growth Co. II	58.96%

Insider Ownership

Company	Insider Ownership
PDP Invesco Dorsey Wright Momentum ETF	N/A
PMN ProMIS Neurosciences	10.30%
RENE Cartesian Growth Co. II	20.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PDP Invesco Dorsey Wright Momentum ETF	N/A	12.89 million	N/A	Optionable
PMN ProMIS Neurosciences	6	18.96 million	17.01 million	Not Optionable
RENE Cartesian Growth Co. II	N/A	21.62 million	17.30 million	Not Optionable

PDP, RENE, and PMN Headlines

Source	Headline
	Short Interest in Cartesian Growth Co. II (NASDAQ:RENE) Increases By 312.5% marketbeat.com - April 25 at 10:22 PM
	Wolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE) marketbeat.com - April 23 at 8:48 PM
	Cartesian Growth Co. II (NASDAQ:RENE) Shares Up 0% americanbankingnews.com - April 19 at 2:58 AM
	Cartesian Growth Co. II (NASDAQ:RENE) Short Interest Update marketbeat.com - March 28 at 8:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Invesco Dorsey Wright Momentum ETF

NASDAQ:PDP

PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.

ProMIS Neurosciences

NASDAQ:PMN

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Cartesian Growth Co. II

NASDAQ:RENE

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial